Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
17 January, 2019 12:55 IST
Zydus Cadila gets USFDA's final nod for Tizanidine tablets
Source: IRIS | 13 Mar, 2018, 11.05AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the USFDA to market Tizanidine Tablets USP in the strengths of 2 mg and 4 mg.

The drug is used to treat muscle spasms caused by certain conditions such as multiple sclerosis, spinal cord injury and works by helping to relax the muscles.

It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

The group now has more than 180 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 11.3, or 2.94%, to trade at  Rs 395.10.  The total volume of shares traded  was  24,840 at the BSE (10.47 a.m., Tuesday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Zydus receives final approval from USFDA for Acetazolamide ER Capsules - 17-Jan-2019 13:27
OnMobile Global renews its contract with Telefonica Moviles Espana, SAU (Telefonica) - 17-Jan-2019 10:14
Suven Life Sciences secures 2 overseas product patents - 16-Jan-2019 13:45
Texmaco Rail & Engineering receives orders worth Rs 2.62 bn - 16-Jan-2019 12:59
Dr Reddy's announces completion of USFDA audit of formulation facility - 16-Jan-2019 10:15
L&T Hydrocarbon consortium wins EPCI order from Saudi Aramco - 15-Jan-2019 10:24
Zydus Cadila gets final approval from USFDA for 2 drugs - 15-Jan-2019 10:20
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer